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ABSTRACT
We used decision analysis techniques with Markov
cohort modeling to examine the role of cancer anti-
gen 125 (CA-125) in follow-up surveillance strate-
gies among patients with advanced ovarian cancer.
Utilities were derived from a societal perspective.
Using quality-adjusted life years (QALYs) as the
outcome variable, the value of CA-125 monitoring
for asymptomatic women with ovarian cancer was
found to be reduced as compared with a strategy that
includes CA-125 testing. Decisions to include
CA-125 in surveillance strategies for ovarian cancer
patients should be made after discussion with full dis-
closure of the preference-sensitive nature of CA-125.
The model demonstrates that preferences and per-
spective can influence decisions in cancer care.
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1. INTRODUCTION
Many authors have reported on the prognostic sig-
nificance of the cancer antigen (CA-125) assay in
ovarian cancer patients 1–3. The assay has become
established in clinical practice, and it is widely used
to monitor response to chemotherapy, including che-
motherapy given in the recurrent setting 4,5. It has also
been used in many academic centres to facilitate early
diagnosis of relapse 6.
Although a rising CA-125 level in a patient with
clinical complete remission is highly predictive of a
symptomatic recurrence (median time to development
of symptoms, physical signs, or radiographic evi-
dence of recurrent disease is 3–6 months), there is
no evidence that immediate treatment with salvage
chemotherapy is more effective than reserving such
treatment until the time that other manifestations of
recurrent disease appear 7–11. Furthermore, patients
have been shown to anticipate the assay results with
heightened anxiety at each follow-up visit, a condi-
tion described as the “CA-125 addiction” 12.
Recurrent ovarian cancer is incurable, and sec-
ond-line therapy is less effective and less tolerated
than is chemotherapy used in the primary setting.
Therefore, the goals of treatment for relapse include
providing disease control and symptom palliation
with a well-tolerated chemotherapy regimen and pro-
viding support and maintenance of good quality of
life (QOL). It is widely accepted that patients who have
symptoms and a rising CA-125 concentration should
start treatment. There is debate regarding whether
asymptomatic patients with recurrence should be
treated, and further, whether CA-125 monitoring
should be a routine component of disease surveil-
lance for women with ovarian cancer. It has been
suggested that, until proof has been developed that
early recognition and treatment of relapse improves
patient outcomes, routine measurement of CA-125
for disease surveillance be abandoned 13.
The precise utility of diagnosing biochemical
ovarian cancer relapse is unknown, but its impact
must be defined in terms of survival, response to sal-
vage chemotherapy, and ultimately, the patient’s
QOL 14. Because of the controversy and the multiple
health and QOL-related issues surrounding the use of
CA-125 assays, decision analysis techniques with
Markov cohort modeling can be useful in quantita-
tively and transparently evaluating the role of CA-
125 in the follow-up management of women with
ovarian cancer. Our objective was to use decision
analysis techniques to examine the role of CA-125
in surveillance strategies for women, based on a so-
cietal perspective.
2. PATIENTS AND METHODS
2.1 Study Population
The population considered within the decision analy-
sis consisted of women with stage III or IV ovarian
cancer who had attained a complete response to pri-
mary treatment for their disease. The median age of
patients presenting with ovarian cancer is 63 years
and the start age for the purposes of the decision
analysis model was therefore set to that level 15.
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2.2 Study Comparators
The decision for or against incorporating CA-125
monitoring into follow-up management allows for
consideration of two alternative strategies:
• Intensive monitoring (that is, with CA-125)
• Non-intensive monitoring (that is, without
CA-125)
Women in the intensive monitoring arm of the
decision analysis were to undergo cyclic CA-125 test-
ing if asymptomatic. All patients with symptomatic
recurrence were to receive second-line chemotherapy.
Because the serum CA-125 test is an imperfect diag-
nostic test, Bayes’ revision was applied to ensure the
use of valid probabilities. The data on the sensitivity
and specificity of the CA-125 test came from a sys-
tematic review completed by our group (submitted
for publication), and the prevalence probability of
advanced stage ovarian cancer came from Canadian
Cancer Statistics 2003 16.
2.3 Markov Model
Figure 1 schematically depicts the various health
states through which a patient can possibly transi-
tion in the decision analysis model. The lifelong
course of events for patients with stages III and IV
ovarian cancer are simulated as a Markov cohort.
At initiation of the model, all women with ova-
rian cancer are assumed to initially have a complete
response to a combination of surgery and chemo-
therapy and to traverse through follow-up time until
all members of the group die or reach 100 years of
age. Over time, a woman can remain well, recur, or
die from recurrence or competing risks. Over a se-
ries of cycles, women move from one state to an-
other as determined by transition probabilities that
can differ with time and age. Cycle length for the
model is 3 months, corresponding with the initial
follow-up interval after completion of primary
therapy.
The average number of cycles before death is used
to determine the life expectancy associated with each
strategy. Time spent in each health state is weighted
by an associated utility value to allow for an estima-
tion of quality-adjusted life years (QALYs).
The model was developed using Data 4.0 soft-
ware (TreeAge Software, Williamstown, MA, U.S.A.)
and Excel 2000 software (Microsoft, Redmond, WA,
U.S.A.) written for use on an IBM personal computer.
2.4 Utility Assessment
Reduction or improvement in QOL resulting from a
diagnosis of recurrence was considered by analyz-
ing QALYs. Utility scores, which combine an
individual’s preferences for a specific health state with
morbidity data, are further combined with informa-
tion on life expectancy to produce the single weighted
measure QALY. “Utility” has been defined as the level
of desirability associated with a particular outcome
or health state 17. No evidence exists in the literature
to describe the associated disutility of being treated
with chemotherapy when asymptomatic (associated
with a true positive CA-125 test or a false positive
CA-125 test) or the utilities of receiving second-line
chemotherapy for a first recurrence, having a com-
plete response to second-line chemotherapy, or re-
ceiving third-line chemotherapy for a second
recurrence. Given that chemotherapy for recurrent
ovarian cancer may cause serious side effects and
have uncertain or limited benefits, the risks of the
therapy must be weighed against its value.
To make decisions regarding preferred therapy,
value judgments are required. In clinical practice, this
type of evaluation is currently made in an informal
and implicit manner. Recent methodologic develop-
ments in shared decision-making now allow for an
explicit assessment of preferences where more than
one option for treatment is available. In utility ap-
proaches, a variety of scaling methods are available
to assign a numeric value on a scale where 0.0 repre-
sents death and 1.0 represents perfect health. Ap-
proaches include the standard gamble, the time
trade-off, and the visual analogue scale (VAS) 18.
For the present study, a convenience sample of
20 women from the community were selected to de-
rive utilities for 8 different health states relevant to
the decision analysis. Respondents had no personal
experience with ovarian cancer. The use of data from
a community sample corresponds with recommen-
dations from The Panel on Cost-Effectiveness in
Health and Medicine, a non-federal panel convened
by the U.S. Public Health Service with expertise in
cost-effectiveness analysis, clinical medicine, ethics,
and health outcomes measurement 19.
Health states were developed based on the at-
tributes of the EuroQOL questionnaire 20 and were
FIGURE 1 Possible options for health state occupation in the
decision analysis model with Markov cohort.PRACTICE GUIDELINE SERIES
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valued using the VAS. The VAS was organized verti-
cally like a thermometer. The 8 different health states
for the decision analysis were organized at the pe-
riphery of the scale. In this way, all health states could
be considered simultaneously. The description of each
health state contained information on 6 different do-
mains of health, including mobility, self-care, main
activity, social relationships, mood, and side effects
of treatment.
2.5 Probability Estimates
Probabilities were derived from published work
where possible, but in some instances, no published
data were available for inclusion in the model. Con-
sequently, expert judgment was required to estimate
some probabilities. Annual recurrence rates for ova-
rian cancer were estimated based on 5-year survival
data for patients with stages III and IV ovarian can-
cer 16,21. Table I gives the probability estimates used
in the decision analysis. To allow for the possibility
of a biochemical recurrence leading to death (because
of surveillance without CA-125), a relative risk of
mortality was added in the non-intensive monitoring
arm for the purposes of Monte Carlo simulation:
logn ( m = 1, s = 0.05 ).
2.6 Assumptions
To keep the model as simple as possible and yet re-
flective of the follow-up characteristics of patients
with advanced ovarian cancer, several assumptions
are made.
Within the model, recurrence rates are assumed
to be constant over time. Although recurrence rates
are known not to be constant over time, this assump-
tion is unlikely to affect the results of the analysis,
because recurrence rates are identical between the
two possible follow-up strategies.
Also, once a patient is diagnosed with a second
recurrence (requiring third-line chemotherapy), no
further complete response will be possible. Patients
in that situation will remain on treatment until death.
Although no evidence describes the frequency and
duration of complete response post third-line chemo-
therapy, clinical experience suggests that very few
patients (fewer than 10%) are likely to reach this
health state. Indeed, it has recently been proposed
that ovarian cancer patients who have achieved a re-
mission following primary therapy not have follow-
up visits until 2 years after completion of their
first-line chemotherapy.
2.7 Analysis of Uncertainty
Uncertainty regarding the expected values of out-
comes of interest was explored through the use of
Monte Carlo simulation. Monte Carlo simulation re-
quires the specification of probability distributions
for all input parameters within the model. Repeated
estimates of outcomes are obtained by re-running the
model using different values for each data input, ran-
domly selected from the probability distributions.
Utility variables for the decision analysis were as-
signed normal distributions. Empiric probability vari-
ables were assigned a beta distribution. Variables
without a known distributional form (that is, those
with assumed values or those with values based on
other published reports) were assigned a triangular
distribution.
In addition to Monte Carlo simulation, uncertainty
was further assessed using sensitivity analysis,
whereby values for key parameters were changed to
assess the sensitivity of results.
3. RESULTS
The results of the analysis are presented in terms of
the expected values of outcomes based on a Monte
Carlo simulation with 3000 replications. Base-case
results are presented for a woman aged 63 who is
diagnosed with ovarian cancer (stage III or IV) and
who has a complete response to primary treatment.
Analysis demonstrates that life expectancy is essen-
tially no different between the two strategies: the ex-
pected difference is 0.0 years [95% confidence
interval (CI): 0.00 to 0.001]. However, the expected
QALY value is slightly higher for non-intensive moni-
toring than for intensive monitoring: a difference of
0.28 years (95% CI: 0.09 to 1.05). Costs are higher
for intensive monitoring as compared with non-in-
tensive monitoring: a difference of $801.63 (95% CI:
$402 to $2099). Table II provides a summary of in-
cremental values from the Monte Carlo simulation.
Overall, non-intensive monitoring is dominant
over intensive monitoring; it is both more effective
(in terms of QALYs) and less costly. This result is con-
sistent across all 3000 Monte Carlo replications (Fig-
ure 2).
3.1 Sensitivity Analysis
We tested the robustness of the overall conclusions
by performing sensitivity analyses. The two main
branches of the model are identical, except for the in-
clusion of the CA-125 test and a possible relative risk
of dying from an unrecognized biochemical relapse.
Intensive monitoring is inferior to non-intensive
monitoring throughout the range of sensitivities and
specificities, owing largely to the effect of preferences
and values associated the health state of being diag-
nosed with a biochemical relapse. Because CA-125
more confidently identifies a biochemical relapse, the
overall expected utility of intensive monitoring de-
creases, as reflected by the fact that the survey par-
ticipants viewed a cancer recurrence quite negatively.
As the specificity of the CA-125 test increases, theHOPKINS et al.
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expected value of intensive monitoring is seen to in-
crease. This result is predictable, because the ability
of a test to accurately “rule out” a disease is desirable.
The sensitivity analysis comparing the two fol-
low-up strategies was performed with variation ac-
cording to the relative risk of death resulting from
failure to diagnose a biochemical relapse. A “thresh-
old” effect was seen at a relative risk value of 1.0.
Indeed, intensive monitoring could be desirable if a
meaningful survival advantage attached to early rec-
TABLE I Probability estimates for ovarian cancer follow-up per 3-month Markov cycle
Variable Reference Variable name Estimate Comments
in model (range)
Probability of death Canada, pD_ASR N/A N/A
due to competing risks 1995 22
Probability of death Estimate pD_Ds1 0.001 Tumour will have some degree of
due to disease at time (0–0.002) resistance to chemotherapy (reflected in
of first symptomatic relapse low response rates)
Probability of death Estimate pD_Ds2 0.01 Assume tumour will have greater
due to disease at time (0–0.02) resistance to chemotherapy
of second relapse
Probability of death Estimate pD_ProgDx 0.1 Progressing on second-line treatment
due to progressive disease (0–0.2) leads to third line chemotherapy or death
Probability of recurrence, Estimate pRecur_OKPostTx2 0.15 All patients will eventually recur
given remission following (0.05–0.25) following second-line chemotherapy
second line chemotherapy
Probability of death Estimate pD_Chemo2 0.001 Assume chemotherapy for symptomatic
due to second-line (0–0.002) recurrenceis platinum, topotecan, or
chemotherapy doxil
Probability of death Estimate pD_Chemo3 0.005 Assume third-line agent is platinum,
due to third-line (0–0.01) topotecan, or doxil, but with cumulative
chemotherapy toxicity and risk
Probability of disease Estimate pProg_Tx2 0.40 Response rates to second line chemo-
progression on (0.20–0.60) therapy is approximately 20%–25%
second-line chemotherapy
Probability of recurrence, Ozols et al., pRecur 0.25 Probability based on 5-year survival rate
given remission after 2001 23; (0.15–0.35) of 25% (range: 15%–35%);
first-line therapy Eltabbakh and assume RR constant over time
Awtrey, 2001 24
Probability of symptomatic Bast et al., pSymp 0.20 Among ovarian cancers, 80% express
recurrence following remission 1983 25 (0.10–0.30) CA-125; patients with CA-125 expres-
after first-line therapy sion will have an asymptomatic
recurrence; remainder (0.2) will be
symptomatic
Probability of a positive Bast et al., pPosTest 0.82 Of 101 patients with surgically proven
CA-125 test 1983 25 Actual data follow ovarian cancer, 83 are CA-125–positive
b distribution
Relative risk of death Estimate RR_Death u=1.00 Value reflects a hypothetical probability
from unrecognized and Asymptomatic (0.91–1.1) of death from an asymptomatic relapse
untreated relapse
TABLE II Incremental results for non-intensive versus intensive monitoring
Summary statistics Life expectancy Difference in
Quality-adjusted Costs
life expectancy
Expected value (mean) 0.00 –0.28 $801.63
Range 0.00 to 0.01 –0.09, –1.05 $341.00, $3619.00
95% CI 0.00 to 0.01 –0.13 to –0.69 $402.00 to $2099.00
CI = confidence interval.PRACTICE GUIDELINE SERIES
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ognition and treatment of recurrence based on el-
evated CA-125 levels.
4. DISCUSSION
Decision analysis allows for clinical problems to be
organized structurally into their component parts. We
developed a decision model to describe the current
options regarding the use of CA-125 in the follow-
up of women with advanced ovarian cancer.
The model highlights the lack of published data
on a number of vitally important statistics in ovarian
cancer, such as the probabilities of dying from com-
plications of chemotherapy and disease burden. No
published information on annual recurrence rates
according to disease stage are available. The absence
of such data is a limitation of this decision analysis.
Clearly, collection of the foregoing information is an
important goal for future work and database devel-
opment in ovarian cancer.
An important attribute of decision analysis is the
possibility of explicitly providing a place for a
patient’s point of view and values. Varying perspec-
tives can be expected to produce variation in the quan-
titative results of decision analysis. For example, it
was previously shown that physicians and patients
do not share a common view about health-related
matters, especially issues relating to pain, physical
status, and psychological wellbeing 26–28. Calhoun
et al. 29 recently published an analysis of utility as-
sessments for various ovarian cancer treatments and
demonstrated that assessments of the impact of che-
motherapy-related toxicity vary depending on the per-
spective of the individual responding to the questions.
Specifically, the study examined perceptions of the
severity of chemotherapy-related toxicity among
physicians, ovarian cancer patients, at-risk women,
and women in the general population. Health states
with toxicity were associated with less favourable
assessments than were health states with no toxicity.
The ovarian cancer patients and the women at risk
for development of ovarian cancer viewed health
states with toxicity similarly and more favourably
than did women in the general population. However,
patient assessments varied depending on whether they
had previously experienced life with toxicity from
chemotherapy. An objective of future work will be
to compare the results of this decision analysis from
a societal perspective with one from a patient per-
spective. The overall results would likely be differ-
ent and reflective of a preference for CA-125 testing.
Most ovarian cancer patients desire tests to assess
their disease status. Information is viewed positively.
With increasing attention to shared decision-mak-
ing in medicine, assessment of patient preferences
will become more mainstream. Physicians must un-
derstand how preference-sensitive inputs can affect
health care decisions. Perspective can have a strong
effect, not only for individual decisions about health
care, but also for the formulation of health policy and
practice guidelines. An example is found in a clini-
cal practice guideline for menorrhagia, published by
the Royal College of Obstetricians and Gynaecolo-
gists in 1998, which recommend that women’s pref-
erences for watchful waiting, medical treatment, or
surgery be considered when decisions are made about
appropriate care.
The benefits of detecting biochemical ovarian
cancer recurrence are uncertain. Currently, there is
no evidence that recognition and treatment of bio-
chemical recurrence has any survival benefit. The
results of an ongoing European trial to address this
question are awaited. In the meantime, the potential
negative impact of a recurrence on QOL indicates that
merit accrues to the evaluation of preferences for
CA-125 testing in surveillance strategies for ova-
rian cancer.
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